Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice - PubMed
7 days ago
- #long-term survival
- #atezolizumab plus bevacizumab
- #hepatocellular carcinoma
- Study evaluates 3-year survival outcomes in unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab plus bevacizumab (Atez/Bev) in real-world clinical settings.
- Multicenter retrospective study included 555 patients with Child-Pugh A and BCLC stage B or C, treated from 2020 to 2021.
- Objective response rate (ORR) was 41.3%, disease control rate (DCR) was 79.4%, median progression-free survival (PFS) was 6.2 months, and median overall survival (OS) was 21.6 months.
- 3-year survival rate was 29.7%, with first-line Atez/Bev users showing a higher rate of 35.9%.
- Post-progression treatment was administered to 54.1% of patients, with a median post-progression survival (PPS) of 10.9 months.
- Conversion therapy was performed in 5.9% of patients, and immune-related adverse events (irAEs) occurred in 13.3% (grade 5: 0.7%).
- Findings suggest Atez/Bev provides good ORR, DCR, and favorable long-term survival in uHCC patients.